Editor's Note A shuttered bariatric surgery center in Oklahoma last month is just one example of how the rise of Glucagon-like peptide-1 (GLP-1) agonists are reshaping health systems’ investments, Axios reported August 13. Rather than “massive hospital towers with cardiology clinics, dialysis beds and joint replacement centers,” the focus is…

Read More

Editor's Note For diabetic patients with obesity and chronic kidney disease (CKD), metabolic bariatric surgery could protect the kidneys better than therapy with glucagon-like peptide-1 receptor agonists (GLP-1RA), according to research published in the September issue of the Annals of Surgery. Conducted at a large US health system, the study…

Read More

Editor's Note Roux-en-Y gastric bypass (RYGB) reduces cardiovascular risk factors independent of calorie restriction and weight loss, according to a recent study published in JAMA Surgery. News-Medical.Net reported on the study July 4. Bariatric surgery, particularly RYGB, is more effective than non-surgical treatments for significant weight reduction and lowering cardiovascular…

Read More

Editor's Note Roux-en-Y gastric bypass surgery kept type 2 diabetes in remission for up to 15 years and maintained most of the weight loss for up to 20 years in a long-term study, according to a June 12 report in SciTech Daily. Presented the same day at The American Society…

Read More

Editor's Note Bariatric surgery provides longer-lasting, more effective weight loss than GLP-1 receptor agonists and lifestyle interventions, according to systematic reviews of medical literature from 2020 to 2024. Medical Xpress reported the news June 11. Presented at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2024 Annual Scientific Meeting,…

Read More

Editor's Note Preoperative use of GLP-1 receptor agonists (RA) medications such as Ozempic and Wegovy is safe, according to a study published in the June issue of the American Journal of Gastroenterology. Controversy has swirled around these drugs due to the risk of slowed stomach emptying increasing a patient’s odds…

Read More

Editor's Note Research shows perioperative weight loss does not consistently improve outcomes or OR times in patients undergoing primary bariatric procedures, including laparoscopic sleeve gastrectomy (LSG) and laparoscopic Roux-en-Y gastric bypass (RYGB). The findings were published in the June issue of the Journal of the American College of Surgeons. Using…

Read More

Editor's Note Semaglutide, the active ingredient in Ozempic diabetes treatment and Wegovy weight-loss treatment, outperformed a placebo and demonstrated capacity to reduce risk of death from kidney-related or cardiovascular causes in a recent study of patients with type 2 diabetes and chronic kidney disease spearheaded by manufacturer Novo Nordisk. Published…

Read More

Editor's Note Indian surgeons used the Apple Vision Pro augmented reality (AR) headset for the first time in a live bariatric surgery in New Delhi, according to a May 20 report from New Delhi Television Ltd (NDTV). Including a sleeve gastric bypass and a Single Anastomosis Duodenal-Ileal (SADI), the May…

Read More

Editor's Note Popular weight-loss \ drug semaglutide could significantly increase risk for repeat operations patients with diabetes who undergo lumbar surgery. According to a May 8 report in Medscape Medical News, the findings are pending review for publication and reportedly provides the first evidence on the impact of semaglutide on…

Read More